Novel heart failure biomarkers: why do we fail to exploit their potential?

References

• Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–2200.
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Card Fail. 2017;23:628–651.
   PubMed Web of Science ®Google Scholar
• Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93:1137–1146.
   PubMed Web of Science ®Google Scholar
• Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013;6:606–619.
   PubMed Web of Science ®Google Scholar
• Chow SL, Maisel AS, Anand I, et al. Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American heart association. Circulation. 2017;135:e1054–e1091.
   PubMed Web of Science ®Google Scholar
• Meijers WC, van der Velde AR, de Boer RA. Biomarkers in heart failure with preserved ejection fraction. Neth Heart J. 2016;24:252–258.
   PubMed Web of Science ®Google Scholar
• de Boer RA, Daniels LB, Maisel AS, et al. State of the art: newer biomarkers in heart failure. Eur J Heart Fail. 2015;17:559–569.
   PubMed Web of Science ®Google Scholar
• Liquori ME, Christenson RH, Collinson PO, et al. Cardiac biomarkers in heart failure. Clin Biochem. 2014;47:327–337.
   PubMed Web of Science ®Google Scholar
• Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263–271.
   PubMed Web of Science ®Google Scholar
• Sabbah HN, Goldstein S. Ventricular remodelling: consequences and therapy. Eur Heart J. 1993;14(Suppl C):24–29.
   PubMed Web of Science ®Google Scholar
• Piek A, de Boer RA, Sillje HH. The fibrosis-cell death axis in heart failure. Heart Fail Rev. 2016;21:199–211.
   PubMed Web of Science ®Google Scholar
• Bernardo BC, Weeks KL, Pretorius L, et al. Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacol Ther. 2010;128:191–227.
   PubMed Web of Science ®Google Scholar
• Weeks KL, McMullen JR. The athlete’s heart vs. the failing heart: can signaling explain the two distinct outcomes? Physiology (Bethesda). 2011;26:97–105.
   PubMed Web of Science ®Google Scholar
• Maillet M, van Berlo JH, Molkentin JD. Molecular basis of physiological heart growth: fundamental concepts and new players. Nat Rev Mol Cell Biol. 2013;14:38–48.
   PubMed Web of Science ®Google Scholar
• Hein S, Arnon E, Kostin S, et al. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation. 2003;107:984–991.
   PubMed Web of Science ®Google Scholar
• Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2017;14:591–602.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick JN, Vannan MA, Narula J, et al. Echocardiography in heart failure: applications, utility, and new horizons. J Am Coll Cardiol. 2007;50:381–396.
   PubMed Web of Science ®Google Scholar
• Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339:321–328.
   PubMed Web of Science ®Google Scholar
• Liang F, Wu J, Garami M, et al. Mechanical strain increases expression of the brain natriuretic peptide gene in rat cardiac myocytes. J Biol Chem. 1997;272:28050–28056.
   PubMed Web of Science ®Google Scholar
• Liang F, Gardner DG. Mechanical strain activates BNP gene transcription through a p38/NF-kappaB-dependent mechanism. J Clin Invest. 1999;104:1603–1612.
   PubMed Web of Science ®Google Scholar
• Kinnunen P, Vuolteenaho O, Ruskoaho H. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching. Endocrinology. 1993;132:1961–1970.
   PubMed Web of Science ®Google Scholar
• Volpe M, Rubattu S, Burnett J, Jr. Natriuretic peptides in cardiovascular diseases: current use and perspectives. Eur Heart J. 2014;35:419–425.
   PubMed Web of Science ®Google Scholar
• Felker GM, Petersen JW, Mark DB. Natriuretic peptides in the diagnosis and management of heart failure. CMAJ. 2006;175:611–617.
   PubMed Web of Science ®Google Scholar
• Cox EJ, Marsh SA. A systematic review of fetal genes as biomarkers of cardiac hypertrophy in rodent models of diabetes. PLoS One. 2014;9:e92903.
   PubMed Web of Science ®Google Scholar
• Buckley MG, Marcus NJ, Yacoub MH. Cardiac peptide stability, aprotinin and room temperature: importance for assessing cardiac function in clinical practice. Clin Sci. 1999;97:689–695.
   PubMed Web of Science ®Google Scholar
• Moertl D, Berger R, Struck J, et al. Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death. J Am Coll Cardiol. 2009;53:1783–1790.
   PubMed Web of Science ®Google Scholar
• Don-Wauchope AC, McKelvie RS. Evidence based application of BNP/NT-proBNP testing in heart failure. Clin Biochem. 2015;48:236–246.
   PubMed Web of Science ®Google Scholar
• Hill SA, Booth RA, Santaguida PL, et al. Use of BNP and NT-proBNP for the diagnosis of heart failure in the emergency department: a systematic review of the evidence. Heart Fail Rev. 2014;19:421–438.
   PubMed Web of Science ®Google Scholar
• Booth RA, Hill SA, Don-Wauchope A, et al. Performance of BNP and NT-proBNP for diagnosis of heart failure in primary care patients: a systematic review. Heart Fail Rev. 2014;19:439–451.
   PubMed Web of Science ®Google Scholar
• Roberts E, Ludman AJ, Dworzynski K, et al. The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. BMJ. 2015;350:h910.
   PubMed Web of Science ®Google Scholar
• Takase H, Dohi Y. Kidney function crucially affects B-type natriuretic peptide (BNP), N-terminal proBNP and their relationship. Eur J Clin Invest. 2014;44:303–308.
   PubMed Web of Science ®Google Scholar
• Clerico A, Giannoni A, Vittorini S, et al. The paradox of low BNP levels in obesity. Heart Fail Rev. 2012;17:81–96.
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.
   PubMed Web of Science ®Google Scholar
• Solomon SD, Claggett B, Desai AS, et al. Influence of ejection fraction on outcomes and efficacy of sacubitril/valsartan (LCZ696) in heart failure with reduced ejection fraction: the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure (PARADIGM-HF) trial. Circ Heart Fail. 2016;9:e002744.
   PubMed Web of Science ®Google Scholar
• Voors AA, Dorhout B, van der Meer P. The potential role of valsartan + AHU377 (LCZ696) in the treatment of heart failure. Expert Opin Investig Drugs. 2013;22:1041–1047.
   PubMed Web of Science ®Google Scholar
• Mair J, Lindahl B, Giannitsis E, et al. Will sacubitril-valsartan diminish the clinical utility of B-type natriuretic peptide testing in acute cardiac care? Eur Heart J Acute Cardiovasc Care. 2017;6:321–328.
   PubMed Web of Science ®Google Scholar
• Omland T, Rosjo H, Giannitsis E, et al. Troponins in heart failure. Clin Chim Acta. 2015;443:78–84.
   PubMed Web of Science ®Google Scholar
• Ricchiuti V, Voss EM, Ney A, et al. Cardiac troponin T isoforms expressed in renal diseased skeletal muscle will not cause false-positive results by the second generation cardiac troponin T assay by Boehringer Mannheim. Clin Chem. 1998;44:1919–1924.
   PubMed Web of Science ®Google Scholar
• Sharma S, Jackson PG, Makan J. Cardiac troponins. J Clin Pathol. 2004;57:1025–1026.
   PubMed Web of Science ®Google Scholar
• de Boer RA, Voors AA, Muntendam P, et al. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail. 2009;11:811–817.
   PubMed Web of Science ®Google Scholar
• Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov. 2008;7:827–840.
   PubMed Web of Science ®Google Scholar
• Pascual-Figal DA, Januzzi JL. The biology of ST2: the international ST2 consensus panel. Am J Cardiol. 2015;115:3B–7B.
   PubMed Web of Science ®Google Scholar
• Yu L, Ruifrok WP, Meissner M, et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail. 2013;6:107–117.
   PubMed Web of Science ®Google Scholar
• Filipe MD, Meijers WC, Rogier van der Velde A, et al. Galectin-3 and heart failure: prognosis, prediction & clinical utility. Clin Chim Acta. 2015;443:48–56.
   PubMed Web of Science ®Google Scholar
• Lok DJ, Lok SI, Bruggink-Andre de la Porte PW, et al. Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol. 2013;102:103–110.
   Web of Science ®Google Scholar
• Michalski B, Trzcinski P, Kupczynska K, et al. The differences in the relationship between diastolic dysfunction, selected biomarkers and collagen turn-over in heart failure patients with preserved and reduced ejection fraction. Cardiol J. 2017;24:35–42.
   PubMed Web of Science ®Google Scholar
• de Boer RA, Yu L, van Veldhuisen DJ. Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep. 2010;7:1–8.
   PubMedGoogle Scholar
• Sharma UC, Pokharel S, van Brakel TJ, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004;110:3121–3128.
   PubMed Web of Science ®Google Scholar
• Liu YH, D'Ambrosio M, Liao TD, et al. N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. Am J Physiol Heart Circ Physiol. 2009;296:H404–H412.
   PubMed Web of Science ®Google Scholar
• Sharma U, Rhaleb NE, Pokharel S, et al. Novel anti-inflammatory mechanisms of N-Acetyl-Ser-Asp-Lys-Pro in hypertension-induced target organ damage. Am J Physiol Heart Circ Physiol. 2008;294:H1226–H1232.
   PubMed Web of Science ®Google Scholar
• Calvier L, Martinez-Martinez E, Miana M, et al. The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries. JACC Heart Fail. 2015;3:59–67.
   PubMed Web of Science ®Google Scholar
• Vergaro G, Prud'homme M, Fazal L, et al. Inhibition of galectin-3 pathway prevents isoproterenol-induced left ventricular dysfunction and fibrosis in mice. Hypertension. 2016;67:606–612.
   PubMed Web of Science ®Google Scholar
• Kim H, Lee J, Hyun JW, et al. Expression and immunohistochemical localization of galectin-3 in various mouse tissues. Cell Biol Int. 2007;31:655–662.
   PubMed Web of Science ®Google Scholar
• Frenay AR, Yu L, van der Velde AR, et al. Pharmacological inhibition of galectin-3 protects against hypertensive nephropathy. Am J Physiol Renal Physiol. 2015;308:F500–F509.
   PubMed Web of Science ®Google Scholar
• Feng W, Wu X, Li S, et al. Association of serum galectin-3 with the acute exacerbation of chronic obstructive pulmonary disease. Med Sci Monit. 2017;23:4612–4618.
   PubMed Web of Science ®Google Scholar
• De Iuliis F, Salerno G, Taglieri L, et al. Circulating neuregulin-1 and galectin-3 can be prognostic markers in breast cancer. Int J Biol Markers. 2017;32:e333–e336.
   PubMed Web of Science ®Google Scholar
• Cheng D, Liang B, Li Y. Serum galectin-3 as a potential marker for gastric cancer. Med Sci Monit. 2015;21:755–760.
   PubMed Web of Science ®Google Scholar
• Martinez-Martinez E, Lopez-Andres N, Jurado-Lopez R, et al. Galectin-3 participates in cardiovascular remodeling associated with obesity. Hypertension. 2015;66:961–969.
   PubMed Web of Science ®Google Scholar
• Stoltze Gaborit F, Bosselmann H, Kistorp C, et al. Galectin 3: association to neurohumoral activity, echocardiographic parameters and renal function in outpatients with heart failure. BMC Cardiovasc Disord. 2016;16:117.
   PubMed Web of Science ®Google Scholar
• Besler C, Lang D, Urban D, et al. Plasma and cardiac galectin-3 in patients with heart failure reflects both inflammation and fibrosis: implications for its use as a biomarker. Circ Heart Fail. 2017;10:pii:e003804.
   Google Scholar
• Grupper A, Nativi-Nicolau J, Maleszewski JJ, et al. Circulating galectin-3 levels are persistently elevated after heart transplantation and are associated with renal dysfunction. JACC Heart Fail. 2016;4:847–856.
   PubMed Web of Science ®Google Scholar
• Mueller T, Dieplinger B, Gegenhuber A, et al. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem. 2008;54:752–756.
   PubMed Web of Science ®Google Scholar
• Pascual-Figal DA, Ordonez-Llanos J, Tornel PL, et al. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. J Am Coll Cardiol. 2009;54:2174–2179.
   PubMed Web of Science ®Google Scholar
• Weinberg EO, Shimpo M, De Keulenaer GW, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002;106:2961–2966.
   PubMed Web of Science ®Google Scholar
• Chen WY, Hong J, Gannon J, et al. Myocardial pressure overload induces systemic inflammation through endothelial cell IL-33. Proc Natl Acad Sci USA. 2015;112:7249–7254.
   PubMed Web of Science ®Google Scholar
• Pascual-Figal DA, Lax A, Perez-Martinez MT, GREAT Network, et al. Clinical relevance of sST2 in cardiac diseases. Clin Chem Lab Med. 2016;54:29–35.
   PubMed Web of Science ®Google Scholar
• Tseng CCS, Huibers MMH, Gaykema LH, et al. Soluble ST2 in end-stage heart failure, before and after support with a left ventricular assist device. Eur J Clin Invest. 2018;48:e12886. DOI: 10.1111/eci.12886
   Web of Science ®Google Scholar
• Bergis D, Kassis V, Radeke HH. High plasma sST2 levels in gastric cancer and their association with metastatic disease. Cancer Biomark. 2016;16:117–125.
   PubMed Web of Science ®Google Scholar
• Lu DP, Zhou XY, Yao LT, et al. Serum soluble ST2 is associated with ER-positive breast cancer. BMC Cancer. 2014;14:198.
   PubMed Web of Science ®Google Scholar
• Samuelsson M, Dereke J, Svensson MK, et al. Soluble plasma proteins ST2 and CD163 as early biomarkers of nephropathy in Swedish patients with diabetes, 15-34 years of age: a prospective cohort study. Diabetol Metab Syndr. 2017;9:41.
   PubMed Web of Science ®Google Scholar
• Jiang SW, Wang P, Xiang XG, et al. Serum soluble ST2 is a promising prognostic biomarker in HBV-related acute-on-chronic liver failure. Hepatobiliary Pancreat Dis Int. 2017;16:181–188.
   PubMed Web of Science ®Google Scholar
• Kirchhoff C, Habben I, Ivell R, et al. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Reprod. 1991;45:350–357.
   PubMed Web of Science ®Google Scholar
• Bingle CD, Vyakarnam A. Novel innate immune functions of the whey acidic protein family. Trends Immunol. 2008;29:444–453.
   PubMed Web of Science ®Google Scholar
• LeBleu VS, Teng Y, O'Connell JT, et al. Identification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosis. Nat Med. 2013;19:227–231.
   PubMed Web of Science ®Google Scholar
• de boer R, Cao Q, Postmus D, et al. The WAP four-disulfide core domain protein HE4: a novel biomarker for heart failure. JACC Heart Fail. 2013;1:164–169.
   PubMed Web of Science ®Google Scholar
• Piek A, Meijers WC, Schroten NF, et al. HE4 Serum levels are associated with heart failure severity in patients with chronic heart failure. J Card Fail. 2017;23:12–19.
   PubMedGoogle Scholar
• Galgano MT, Hampton GM, Frierson HF, Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006;19:847–853.
   PubMed Web of Science ®Google Scholar
• Hertlein L, Stieber P, Kirschenhofer A, et al. Human epididymis protein 4 (HE4) in benign and malignant diseases. Clin Chem Lab Med. 2012;50:2181–2188.
   PubMed Web of Science ®Google Scholar
• Kemal YN, Demirag GN, Bedir AM, et al. Serum human epididymis protein 4 levels in colorectal cancer patients. Mol Clin Oncol. 2017;7:481–485.
   PubMedGoogle Scholar
• Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003;63:3695–3700.
   PubMed Web of Science ®Google Scholar
• Wan J, Wang Y, Cai G, et al. Elevated serum concentrations of HE4 as a novel biomarker of disease severity and renal fibrosis in kidney disease. Oncotarget. 2016;7:67748–67759.
   PubMedGoogle Scholar
• Nagy B, Jr., Krasznai ZT, Balla H, et al. Elevated human epididymis protein 4 concentrations in chronic kidney disease. Ann Clin Biochem. 2012;49:377–380.
   PubMed Web of Science ®Google Scholar
• Liu LCY, Valente MAE, Postmus D, et al. Identifying subpopulations with distinct response to treatment using plasma biomarkers in acute heart failure: results from the PROTECT trial: differential response in acute heart failure. Cardiovasc Drugs Ther. 2017;31:281–293.
   PubMed Web of Science ®Google Scholar
• Evdokimova V, Tognon CE, Benatar T, et al. IGFBP7 binds to the IGF-1 receptor and blocks its activation by insulin-like growth factors. Sci Signal. 2012;5:ra92.
   PubMed Web of Science ®Google Scholar
• Akiel M, Rajasekaran D, Gredler R, et al. Emerging role of insulin-like growth factor-binding protein 7 in hepatocellular carcinoma. J Hepatocell Carcinoma. 2014;1:9–19.
   PubMedGoogle Scholar
• Yamanaka Y, Wilson EM, Rosenfeld RG, et al. Inhibition of insulin receptor activation by insulin-like growth factor binding proteins. J Biol Chem. 1997;272:30729–30734.
   PubMed Web of Science ®Google Scholar
• Chugh S, Ouzounian M, Lu Z, et al. Pilot study identifying myosin heavy chain 7, desmin, insulin-like growth factor 7, and annexin A2 as circulating biomarkers of human heart failure. Proteomics. 2013;13:2324–2334.
   PubMed Web of Science ®Google Scholar
• Gandhi PU, Gaggin HK, Sheftel AD, et al. Prognostic usefulness of insulin-like growth factor-binding protein 7 in heart failure with reduced ejection fraction: a novel biomarker of myocardial diastolic function? Am J Cardiol. 2014;114:1543–1549.
   PubMed Web of Science ®Google Scholar
• Gandhi PU, Chow SL, Rector TS, et al. Prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction. J Card Fail. 2017;23:20–28.
   PubMed Web of Science ®Google Scholar
• Barroso MC, Kramer F, Greene SJ, et al. Serum insulin-like growth factor-1 and its binding protein-7: potential novel biomarkers for heart failure with preserved ejection fraction. BMC Cardiovasc Disord. 2016;16:199.
   PubMed Web of Science ®Google Scholar
• Liu Y, Wu M, Ling J, et al. Serum IGFBP7 levels associate with insulin resistance and the risk of metabolic syndrome in a Chinese population. Sci Rep. 2015;5:10227.
   PubMed Web of Science ®Google Scholar
• Meersch M, Schmidt C, Van Aken H, et al. Urinary TIMP-2 and IGFBP7 as early biomarkers of acute kidney injury and renal recovery following cardiac surgery. PLoS One. 2014;9:e93460.
   PubMed Web of Science ®Google Scholar
• Schanz M, Shi J, Wasser C, et al. Urinary [TIMP-2] x [IGFBP7] for risk prediction of acute kidney injury in decompensated heart failure. Clin Cardiol. 2017;40:485–491.
   PubMed Web of Science ®Google Scholar
• Pilarczyk K, Edayadiyil-Dudasova M, Wendt D, et al. Urinary [TIMP-2]*[IGFBP7] for early prediction of acute kidney injury after coronary artery bypass surgery. Ann Intensive Care. 2015;5:50.
   PubMed Web of Science ®Google Scholar
• Oezkur M, Magyar A, Thomas P, et al. TIMP-2*IGFBP7 (Nephrocheck(R)) measurements at intensive care unit admission after cardiac surgery are predictive for acute kidney injury within 48 hours. Kidney Blood Press Res. 2017;42:456–467.
   PubMed Web of Science ®Google Scholar
• Kutsukake M, Ishihara R, Momose K, et al. Circulating IGF-binding protein 7 (IGFBP7) levels are elevated in patients with endometriosis or undergoing diabetic hemodialysis. Reprod Biol Endocrinol. 2008;6:54.
   PubMed Web of Science ®Google Scholar
• Benassi MS, Pazzaglia L, Novello C, et al. Tissue and serum IGFBP7 protein as biomarker in high-grade soft tissue sarcoma. Am J Cancer Res. 2015;5:3446–3454.
   PubMed Web of Science ®Google Scholar
• Ruan W, Wu M, Shi L, et al. Serum levels of IGFBP7 are elevated during acute exacerbation in COPD patients. Int J Chron Obstruct Pulmon Dis. 2017;12:1775–1780.
   PubMed Web of Science ®Google Scholar
• Otaki Y, Watanabe T, Kubota I. Heart-type fatty acid-binding protein in cardiovascular disease: a systemic review. Clin Chim Acta. 2017;474:44–53.
   PubMed Web of Science ®Google Scholar
• Okamoto F, Sohmiya K, Ohkaru Y, et al. Human heart-type cytoplasmic fatty acid-binding protein (H-FABP) for the diagnosis of acute myocardial infarction. Clinical evaluation of H-FABP in comparison with myoglobin and creatine kinase isoenzyme MB. Clin Chem Lab Med. 2000;38:231–238.
   PubMed Web of Science ®Google Scholar
• Aartsen WM, Pelsers MM, Hermens WT, et al. Heart fatty acid binding protein and cardiac troponin T plasma concentrations as markers for myocardial infarction after coronary artery ligation in mice. Pflugers Arch. 2000;439:416–422.
   PubMed Web of Science ®Google Scholar
• Kleine AH, Glatz JF, Van Nieuwenhoven FA, et al. Release of heart fatty acid-binding protein into plasma after acute myocardial infarction in man. Mol Cell Biochem. 1992;116:155–162.
   PubMed Web of Science ®Google Scholar
• Ishii J, Ozaki Y, Lu J, et al. Prognostic value of serum concentration of heart-type fatty acid-binding protein relative to cardiac troponin T on admission in the early hours of acute coronary syndrome. Clin Chem. 2005;51:1397–1404.
   PubMed Web of Science ®Google Scholar
• Viswanathan K, Kilcullen N, Morrell C, et al. Heart-type fatty acid-binding protein predicts long-term mortality and re-infarction in consecutive patients with suspected acute coronary syndrome who are troponin-negative. J Am Coll Cardiol. 2010;55:2590–2598.
   PubMed Web of Science ®Google Scholar
• Kutsuzawa D, Arimoto T, Watanabe T, et al. Ongoing myocardial damage in patients with heart failure and preserved ejection fraction. J Cardiol. 2012;60:454–461.
   PubMed Web of Science ®Google Scholar
• Niizeki T, Takeishi Y, Arimoto T, et al. Heart-type fatty acid-binding protein is more sensitive than troponin T to detect the ongoing myocardial damage in chronic heart failure patients. J Card Fail. 2007;13:120–127.
   PubMed Web of Science ®Google Scholar
• Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov. 2008;7:489–503.
   PubMed Web of Science ®Google Scholar
• Binas B, Danneberg H, McWhir J, et al. Requirement for the heart-type fatty acid binding protein in cardiac fatty acid utilization. FASEB J. 1999;13:805–812.
   PubMedGoogle Scholar
• Murphy EJ, Barcelo-Coblijn G, Binas B, et al. Heart fatty acid uptake is decreased in heart fatty acid-binding protein gene-ablated mice. J Biol Chem. 2004;279:34481–34488.
   PubMedGoogle Scholar
• Fontes JA, Rose NR, Cihakova D. The varying faces of IL-6: from cardiac protection to cardiac failure. Cytokine. 2015;74:62–68.
   PubMed Web of Science ®Google Scholar
• Askevold ET, Gullestad L, Dahl CP, et al. Interleukin-6 signaling, soluble glycoprotein 130, and inflammation in heart failure. Curr Heart Fail Rep. 2014;11:146–155.
   PubMedGoogle Scholar
• Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium, Swerdlow DI, Holmes MV, et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet. 2012;379:1214–1224.
   PubMed Web of Science ®Google Scholar
• Hartman MH, Vreeswijk-Baudoin I, Groot HE, et al. Inhibition of interleukin-6 receptor in a murine model of myocardial ischemia-reperfusion. PLoS One. 2016;11:e0167195.
   PubMed Web of Science ®Google Scholar
• Holte E, Kleveland O, Ueland T, et al. Effect of interleukin-6 inhibition on coronary microvascular and endothelial function in myocardial infarction. Heart 2017;103:1521–1527.
   PubMed Web of Science ®Google Scholar
• AlBadri A, Lai K, Wei J, et al. Inflammatory biomarkers as predictors of heart failure in women without obstructive coronary artery disease: a report from the NHLBI-sponsored Women’s Ischemia Syndrome Evaluation (WISE). PLoS One. 2017;12:e0177684.
   PubMed Web of Science ®Google Scholar
• Kalogeropoulos A, Georgiopoulou V, Psaty BM, et al. Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study. J Am Coll Cardiol. 2010;55:2129–2137.
   PubMed Web of Science ®Google Scholar
• Kobusiak-Prokopowicz M, Jolda-Mydlowska B, Grzebieniak T, et al. Expression of proinflammatory factors, proangiogenic factors and endostatin in patients with heart failure and different grades of collateral circulation development. Adv Clin Exp Med. 2015;24:987–994.
   PubMed Web of Science ®Google Scholar
• Boulogne M, Sadoune M, Launay JM, et al. Inflammation versus mechanical stretch biomarkers over time in acutely decompensated heart failure with reduced ejection fraction. Int J Cardiol. 2017;226:53–59.
   PubMed Web of Science ®Google Scholar
• Ueland T, Gullestad L, Nymo SH, et al. Inflammatory cytokines as biomarkers in heart failure. Clin Chim Acta. 2015;443:71–77.
   PubMed Web of Science ®Google Scholar
• Demissei BG, Valente MA, Cleland JG, et al. Optimizing clinical use of biomarkers in high-risk acute heart failure patients. Eur J Heart Fail. 2016;18:269–280.
   PubMed Web of Science ®Google Scholar
• Rettig TC, Verwijmeren L, Dijkstra IM, et al. Postoperative interleukin-6 level and early detection of complications after elective major abdominal surgery. Ann Surg. 2016;263:1207–1212.
   PubMed Web of Science ®Google Scholar
• Bunevicius A, Kazlauskas H, Raskauskiene N, et al. Role of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and inteleukin-6 in predicting a poor outcome after a stroke. Neuroimmunomodulation. 2015;22:365–372.
   PubMed Web of Science ®Google Scholar
• Bootcov MR, Bauskin AR, Valenzuela SM, et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci USA. 1997;94:11514–11519.
   PubMed Web of Science ®Google Scholar
• Kempf T, Eden M, Strelau J, et al. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res. 2006;98:351–360.
   PubMed Web of Science ®Google Scholar
• Kempf T, Zarbock A, Widera C, et al. GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med. 2011;17:581–588.
   PubMed Web of Science ®Google Scholar
• Xu J, Kimball TR, Lorenz JN, et al. GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res. 2006;98:342–350.
   PubMed Web of Science ®Google Scholar
• Wollert KC, Kempf T, Peter T, et al. Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation. 2007;115:962–971.
   PubMed Web of Science ®Google Scholar
• Kempf T, von Haehling S, Peter T, et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol. 2007;50:1054–1060.
   PubMed Web of Science ®Google Scholar
• Kempf T, Bjorklund E, Olofsson S, et al. Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction. Eur Heart J. 2007;28:2858–2865.
   PubMed Web of Science ®Google Scholar
• Lankeit M, Kempf T, Dellas C, et al. Growth differentiation factor-15 for prognostic assessment of patients with acute pulmonary embolism. Am J Respir Crit Care Med. 2008;177:1018–1025.
   PubMed Web of Science ®Google Scholar
• Nickel N, Kempf T, Tapken H, et al. Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2008;178:534–541.
   PubMed Web of Science ®Google Scholar
• Mueller T, Leitner I, Egger M, et al. Association of the biomarkers soluble ST2, galectin-3 and growth-differentiation factor-15 with heart failure and other non-cardiac diseases. Clin Chim Acta. 2015;445:155–160.
   PubMed Web of Science ®Google Scholar
• Richter B, Koller L, Hohensinner PJ, et al. A multi-biomarker risk score improves prediction of long-term mortality in patients with advanced heart failure. Int J Cardiol. 2013;168:1251–1257.
   PubMed Web of Science ®Google Scholar
• Mockel M, Searle J, Maisel A. The role of procalcitonin in acute heart failure patients. ESC Heart Fail. 2017;4:203–208.
   PubMed Web of Science ®Google Scholar
• Maisel AS, Choudhary R. Biomarkers in acute heart failure-state of the art. Nat Rev Cardiol. 2012;9:478–490.
   PubMed Web of Science ®Google Scholar
• Wang W, Zhang X, Ge N, et al. Procalcitonin testing for diagnosis and short-term prognosis in bacterial infection complicated by congestive heart failure: a multicenter analysis of 4,698 cases. Crit Care. 2014;18:R4.
   PubMed Web of Science ®Google Scholar
• Maisel A, Neath SX, Landsberg J, et al. Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (Biomarkers in Acute Heart Failure) trial. Eur J Heart Fail. 2012;14:278–286.
   PubMed Web of Science ®Google Scholar
• Mollar A, Villanueva MP, Carratala A, et al. Determinants of procalcitonin concentration in acute heart failure. Int J Cardiol. 2014;177:532–534.
   PubMed Web of Science ®Google Scholar
• Hinson JP, Kapas S, Smith DM. Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev. 2000;21:138–167.
   PubMed Web of Science ®Google Scholar
• Valenzuela-Sanchez F, Valenzuela-Mendez B, Rodriguez-Gutierrez JF, et al. New role of biomarkers: mid-regional pro-adrenomedullin, the biomarker of organ failure. Ann Transl Med. 2016;4:329.
   PubMed Web of Science ®Google Scholar
• Maisel A, Mueller C, Nowak R, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol. 2010;55:2062–2076.
   PubMed Web of Science ®Google Scholar
• Self WH, Storrow AB, Hartmann O, et al. Plasma bioactive adrenomedullin as a prognostic biomarker in acute heart failure. Am J Emerg Med. 2016;34:257–262.
   PubMed Web of Science ®Google Scholar
• Brouwers FP, de Boer RA, van der Harst P, et al. Influence of age on the prognostic value of mid-regional pro-adrenomedullin in the general population. Heart. 2012;98:1348–1353.
   PubMed Web of Science ®Google Scholar
• Singh JSS, Burrell LM, Cherif M, et al. Sacubitril/valsartan: beyond natriuretic peptides. Heart. 2017;103:1569–1577.
   PubMed Web of Science ®Google Scholar
• Cines DB, Pollak ES, Buck CA, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood. 1998;91:3527–3561.
   PubMed Web of Science ®Google Scholar
• Chong AY, Blann AD, Lip GY. Assessment of endothelial damage and dysfunction: observations in relation to heart failure. QJM. 2003;96:253–267.
   PubMed Web of Science ®Google Scholar
• Bardin N, Anfosso F, Masse JM, et al. Identification of CD146 as a component of the endothelial junction involved in the control of cell-cell cohesion. Blood. 2001;98:3677–3684.
   PubMed Web of Science ®Google Scholar
• Wang Z, Yan X. CD146, a multi-functional molecule beyond adhesion. Cancer Lett. 2013;330:150–162.
   PubMed Web of Science ®Google Scholar
• Stalin J, Harhouri K, Hubert L, et al. Soluble melanoma cell adhesion molecule (sMCAM/sCD146) promotes angiogenic effects on endothelial progenitor cells through angiomotin. J Biol Chem. 2013;288:8991–9000.
   PubMed Web of Science ®Google Scholar
• Erdbruegger U, Haubitz M, Woywodt A. Circulating endothelial cells: a novel marker of endothelial damage. Clin Chim Acta. 2006;373:17–26.
   PubMed Web of Science ®Google Scholar
• Harhouri K, Kebir A, Guillet B, et al. Soluble CD146 displays angiogenic properties and promotes neovascularization in experimental hind-limb ischemia. Blood. 2010;115:3843–3851.
   PubMed Web of Science ®Google Scholar
• Qian YN, Luo YT, Duan HX, et al. Adhesion molecule CD146 and its soluble form correlate well with carotid atherosclerosis and plaque instability. CNS Neurosci Ther. 2014;20:438–445.
   PubMed Web of Science ®Google Scholar
• Gayat E, Caillard A, Laribi S, et al. Soluble CD146, a new endothelial biomarker of acutely decompensated heart failure. Int J Cardiol. 2015;199:241–247.
   PubMed Web of Science ®Google Scholar
• Kubena P, Arrigo M, Parenica J, et al. Plasma levels of soluble CD146 reflect the severity of pulmonary congestion better than brain natriuretic peptide in acute coronary syndrome. Ann Lab Med. 2016;36:300–305.
   PubMed Web of Science ®Google Scholar
• Arrigo M, Truong QA, Onat D, et al. Soluble CD146 is a novel marker of systemic congestion in heart failure patients: an experimental mechanistic and transcardiac clinical study. Clin Chem. 2017;63:386–393.
   PubMed Web of Science ®Google Scholar
• Nomikou E, Alexopoulou A, Vasilieva L, et al. Soluble CD146, a novel endothelial marker, is related to the severity of liver disease. Scand J Gastroenterol. 2015;50:577–583.
   PubMed Web of Science ®Google Scholar
• Ciftci Dogansen S, Helvaci A, Adas M, et al. The relationship between early atherosclerosis and endothelial dysfunction in type 1 diabetic patients as evidenced by measurement of carotid intima-media thickness and soluble CD146 levels: a cross sectional study. Cardiovasc Diabetol. 2013;12:153.
   PubMed Web of Science ®Google Scholar
• Kratzer A, Chu HW, Salys J, et al. Endothelial cell adhesion molecule CD146: implications for its role in the pathogenesis of COPD. J Pathol. 2013;230:388–398.
   PubMed Web of Science ®Google Scholar
• Bardin N, Moal V, Anfosso F, et al. Soluble CD146, a novel endothelial marker, is increased in physiopathological settings linked to endothelial junctional alteration. Thromb Haemost. 2003;90:915–920.
   PubMed Web of Science ®Google Scholar
• Vegter EL, van der Meer P, de Windt LJ, et al. MicroRNAs in heart failure: from biomarker to target for therapy. Eur J Heart Fail. 2016;18:457–468.
   PubMed Web of Science ®Google Scholar
• Bernstein E, Kim SY, Carmell MA, et al. Dicer is essential for mouse development. Nat Genet. 2003;35:215–217.
   PubMed Web of Science ®Google Scholar
• Thum T, Galuppo P, Wolf C, et al. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation. 2007;116:258–267.
   PubMed Web of Science ®Google Scholar
• Hong Y, Cao H, Wang Q, et al. Mir-22 may suppress fibrogenesis by targeting TGFbetaR I in cardiac fibroblasts. Cell Physiol Biochem. 2016;40:1345–1353.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Zhang X, Fan S, et al. MicroRNA-497 inhibits cardiac hypertrophy by targeting Sirt4. PLoS One. 2016;11:e0168078.
   PubMed Web of Science ®Google Scholar
• Heggermont WA, Papageorgiou AP, Quaegebeur A, et al. Inhibition of MICRORNA-146a and overexpression of its target dihydrolipoyl succinyltransferase protect against pressure overload-induced cardiac hypertrophy and dysfunction. Circulation. 2017;136:747–761.
   PubMed Web of Science ®Google Scholar
• Montgomery RL, Hullinger TG, Semus HM, et al. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation. 2011;124:1537–1547.
   PubMed Web of Science ®Google Scholar
• Villar AV, Garcia R, Merino D, et al. Myocardial and circulating levels of microRNA-21 reflect left ventricular fibrosis in aortic stenosis patients. Int J Cardiol. 2013;167:2875–2881.
   PubMed Web of Science ®Google Scholar
• Roncarati R, Viviani Anselmi C, Losi MA, et al. Circulating miR-29a, among other up-regulated microRNAs, is the only biomarker for both hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2014;63:920–927.
   PubMed Web of Science ®Google Scholar
• Lv P, Zhou M, He J, et al. Circulating miR-208b and miR-34a are associated with left ventricular remodeling after acute myocardial infarction. Int J Mol Sci. 2014;15:5774–5788.
   PubMed Web of Science ®Google Scholar
• van Boven N, Akkerhuis KM, Anroedh SS, et al. Serially measured circulating miR-22-3p is a biomarker for adverse clinical outcome in patients with chronic heart failure: the Bio-SHiFT study. Int J Cardiol. 2017;235:124–132.
   PubMed Web of Science ®Google Scholar
• Chen MC, Chang TH, Chang JP, et al. Circulating miR-148b-3p and miR-409-3p as biomarkers for heart failure in patients with mitral regurgitation. Int J Cardiol. 2016;222:148–154.
   PubMed Web of Science ®Google Scholar
• Ovchinnikova ES, Schmitter D, Vegter EL, et al. Signature of circulating microRNAs in patients with acute heart failure. Eur J Heart Fail. 2016;18:414–423.
   PubMed Web of Science ®Google Scholar
• Vegter EL, Schmitter D, Hagemeijer Y, et al. Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failure. Int J Cardiol. 2016;224:231–239.
   PubMed Web of Science ®Google Scholar
• Bruno N, ter Maaten JM, Ovchinnikova ES, et al. MicroRNAs relate to early worsening of renal function in patients with acute heart failure. Int J Cardiol. 2016;203:564–569.
   PubMed Web of Science ®Google Scholar
• Vegter EL, Ovchinnikova ES, Sillje HHW, et al. Rodent heart failure models do not reflect the human circulating microRNA signature in heart failure. PLoS One. 2017;12:e0177242.
   PubMed Web of Science ®Google Scholar
• Vegter EL, van der Meer P, Voors AA. Associations between volume status and circulating microRNAs in acute heart failure. Eur J Heart Fail. 2017;19:1077–1078.
   PubMed Web of Science ®Google Scholar
• Hunter WG, Kelly JP, McGarrah RW, 3rd, et al. Metabolic dysfunction in heart failure: diagnostic, prognostic, and pathophysiologic insights from metabolomic profiling. Curr Heart Fail Rep. 2016;13:119–131.
   PubMedGoogle Scholar
• Desmoulin F, Galinier M, Trouillet C, et al. Metabonomics analysis of plasma reveals the lactate to cholesterol ratio as an independent prognostic factor of short-term mortality in acute heart failure. PLoS One. 2013;8:e60737.
   PubMed Web of Science ®Google Scholar
• Cheng ML, Wang CH, Shiao MS, et al. Metabolic disturbances identified in plasma are associated with outcomes in patients with heart failure: diagnostic and prognostic value of metabolomics. J Am Coll Cardiol. 2015;65:1509–1520.
   PubMed Web of Science ®Google Scholar
• Pello AM, Cristobal C, Tarin N, et al. Differential profile in inflammatory and mineral metabolism biomarkers in patients with ischemic heart disease without classical coronary risk factors. J Cardiol. 2015;66:22–27.
   PubMed Web of Science ®Google Scholar
• Mueller-Hennessen M, Dungen HD, Lutz M, et al. A novel lipid biomarker panel for the detection of heart failure with reduced ejection fraction. Clin Chem. 2017;63:267–277.
   PubMed Web of Science ®Google Scholar
• Lindahl A, Forshed J, Nordstrom A. Overlap in serum metabolic profiles between non-related diseases: implications for LC-MS metabolomics biomarker discovery. Biochem Biophys Res Commun. 2016;478:1472–1477.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Heaney LM, Bhandari SS, et al. Trimethylamine N-oxide and prognosis in acute heart failure. Heart. 2016;102:841–848.
   PubMed Web of Science ®Google Scholar
• Ottiger M, Nickler M, Steuer C, et al. Trimethylamine-N-oxide (TMAO) predicts fatal outcomes in community-acquired pneumonia patients without evident coronary artery disease. Eur J Intern Med. 2016;36:67–73.
   PubMed Web of Science ®Google Scholar
• van der Pol A, Gil A, Sillje HHW, et al. Accumulation of 5-oxoproline in myocardial dysfunction and the protective effects of OPLAH. Sci Transl Med. 2017;9:eaam8574.
   PubMed Web of Science ®Google Scholar
• Hlatky MA, Greenland P, Arnett DK, et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation. 2009;119:2408–2416.
   PubMed Web of Science ®Google Scholar
• Ahmad T, Fiuzat M, Pencina MJ, et al. Charting a roadmap for heart failure biomarker studies. JACC Heart Fail. 2014;2:477–488.
   PubMed Web of Science ®Google Scholar
• Kilkenny C, Browne WJ, Cuthill IC, et al. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010;8:e1000412.
   PubMed Web of Science ®Google Scholar
• Demissei BG, Cotter G, Prescott MF, et al. A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial. Eur J Heart Fail. 2017;19:1001–1010.
   PubMed Web of Science ®Google Scholar
• Deutscher SL, Figueroa SD, Kumar SR. Tumor targeting and SPECT imaging properties of an (111)In-labeled galectin-3 binding peptide in prostate carcinoma. Nucl Med Biol. 2009;36:137–146.
   PubMed Web of Science ®Google Scholar
• D'Alessandria C, Braesch-Andersen S, Bejo K, et al. Noninvasive in vivo imaging and biologic characterization of thyroid tumors by ImmunoPET targeting of Galectin-3. Cancer Res. 2016;76:3583–3592.
   PubMed Web of Science ®Google Scholar
• Taegtmeyer H, Sen S, Vela D. Return to the fetal gene program: a suggested metabolic link to gene expression in the heart. Ann N Y Acad Sci. 2010;1188:191–198.
   PubMed Web of Science ®Google Scholar
• Simo-Servat O, Simo R, Hernandez C. Circulating biomarkers of diabetic retinopathy: an overview based on physiopathology. J Diabetes Res. 2016;2016:5263798.
   PubMed Web of Science ®Google Scholar
• Viasus D, Del Rio-Pertuz G, Simonetti AF, et al. Biomarkers for predicting short-term mortality in community-acquired pneumonia: a systematic review and meta-analysis. J Infect. 2016;72:273–282.
   PubMed Web of Science ®Google Scholar
• Schuetz P, Marlowe RJ, Mueller B. The prognostic blood biomarker proadrenomedullin for outcome prediction in patients with chronic obstructive pulmonary disease (COPD): a qualitative clinical review. Clin Chem Lab Med. 2015;53:521–539.
   PubMed Web of Science ®Google Scholar